Apnimed, Inc. Common Stock (APMD) Stock
NYSE · APMD
26.22
Fundamentals
Market cap
$1.21B
Price / Earnings ratio
-9.4x
Price / Sales ratio
31.4x
Price / Book ratio
-6.8x
Return on assets
N/A
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.0%
Debt / Equity ratio
N/A
Latest news
About Apnimed, Inc. Common Stock
Apnimed is a late-stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases
SectorHealthcare
IndustryBiotechnology
Employees81
CEOMr. Kevin Robert Lind
IPO DateJul 31, 2026
HeadquartersCambridge, MA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Kevin Robert Lind | CEO & Director | 1976 |
| Dr. Lawrence G. Miller M.D., M.P.H. | Founder & Vice Chair of the Board | 1954 |
| Mr. Dennis Patrick Molnar M.B.A. | President & COO | 1969 |
| Dr. Luigi Taranto Montemurro M.D. | Co-Founder & Chief Scientific Officer | 1979 |
| Mr. Michael B. Kelly | Chief Financial Officer | 1975 |
| Ms. Leila Sylvain | Senior Manager of Administration | — |
| Mr. Steven W. Spector J.D. | Chief Legal Officer & Head of Corporate Affairs | 1965 |
| Ms. Jennifer Patterson | Senior Vice President of Human Resources | — |
| Dr. John W. Cronin M.D. | Chief Medical Officer | 1968 |
| Dr. Sean M. Johnston M.B.A., Ph.D. | Consulting Head of CMC | 1958 |
Fundamentals
Valuation
Market cap$1.21B
Price-to-sales ratio31.39
Price-to-book value-6.85
Price-earnings ratio-9.40
Return on EquityN/A
Return on SalesN/A
Return on AssetsN/A
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-23.76
Income Statement
Average volume477,428
EBITDAN/A
1 year high (52w)$35.29
1 year low (52w)$16.12
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



